Rexahn Announces Presentation of RX-3117 Data at the 2019 ASCO Gastrointestinal Cancers Symposium
January 14 2019 - 8:00AM
Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage
biopharmaceutical company developing innovative therapies to
improve patient outcomes in cancers that are difficult to treat,
today announced that it will present updated preliminary safety and
efficacy data from the ongoing Phase 2a clinical trial of RX-3117
in combination with ABRAXANE® in first-line metastatic pancreatic
cancer patients at the 2019 American Society of Clinical Oncology
(ASCO) Gastrointestinal (GI) Cancers Symposium being held January
17-19, 2019 at the Moscone West Building in San Francisco, CA.
The poster will be presented on Friday, January
18, 2019 at 11:30 AM-1:00 PM and 5:30 PM-6:30 PM PST. A copy of the
poster being presented will be available on the Company's website
at https://www.rexahn.com/news-media/posters beginning at 10:00 AM
EST on Friday, January 18, 2019.
Details of the poster presentation are
as follows:
Title: A phase 1/2 study of
RX-3117, an oral antimetabolite nucleoside, in combination with
nab-paclitaxel (nab-pac) as first line treatment of metastatic
pancreatic cancer (met-PC): Preliminary results. Abstract
Number: 420Poster Board:
M20Session Information: Poster Session B: Cancers
of the Pancreas, Small Bowel, and Hepatobiliary Tract
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE American: RNN) is a clinical
stage biopharmaceutical company developing innovative therapies to
improve patient outcomes in cancers that are difficult to treat.
The Company’s mission is to improve the lives of cancer patients by
developing next-generation cancer therapies that are designed to
maximize efficacy while minimizing the toxicity and side effects
traditionally associated with cancer treatment. Rexahn’s product
candidates work by targeting and neutralizing specific proteins
believed to be involved in the complex biological cascade that
leads to cancer cell growth. Preclinical studies show that several
of Rexahn’s product candidates may be effective against multiple
types of cancer, including drug resistant cancers, and
difficult-to-treat cancers and others may augment the effectiveness
of current FDA-approved cancer treatments. The Company has two
oncology product candidates, RX-3117 and RX-5902, in Phase 2
clinical development and additional compounds in preclinical
development, including RX-0301. For more information about the
Company and its oncology programs, please visit www.rexahn.com.
Safe HarborTo the extent any statements made in
this press release deal with information that is not historical,
these are forward-looking statements under the Private Securities
Litigation Reform Act of 1995. Such statements include, but are not
limited to, statements about Rexahn’s plans, objectives,
expectations and intentions with respect to the ongoing Phase 2a
clinical trial of RX-3117 in combination with Abraxane®, future
operations and products, the path of clinical trials and
development activities, and other statements identified by words
such as “will,” “potential,” “could,” “can,” “believe,” “intends,”
“continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,”
other words of similar meaning or the use of future dates.
Forward-looking statements by their nature address matters that
are, to different degrees, uncertain. Uncertainties and risks may
cause Rexahn’s actual results to be materially different than those
expressed in or implied by Rexahn’s forward-looking statements. For
Rexahn, particular uncertainties and risks include, among others,
understandings and beliefs regarding the role of certain biological
mechanisms and processes in cancer; drug candidates being in early
stages of development, including clinical development; the ability
to initially develop drug candidates for orphan indications to
reduce the time-to-market and take advantage of certain incentives
provided by the U.S. Food and Drug Administration; the ability to
transition from our initial focus on developing drug candidates for
orphan indications to candidates for more highly prevalent
indications; and the expecting timing of results from our clinical
trials. More detailed information on these and additional factors
that could affect Rexahn’s actual results are described in Rexahn’s
filings with the Securities and Exchange Commission, including its
most recent annual report on Form 10-K and subsequent quarterly
reports on Form 10-Q. All forward-looking statements in this news
release speak only as of the date of this news release. Rexahn
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Media Contact:DGI CommSusan Forman or Laura
Radocaj+1-212-825-3210sforman@dgicomm.comlradocaj@dgicomm.com
Investor Contact:ir@rexahn.com
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Sep 2023 to Sep 2024